Treatment guidelines recommend single-tablet regimens for patients with HIV infection starting antiretroviral therapy. These regimens might be as effective and cost less if taken as separate drugs. We assessed whether the one pill once a day combination of efavirenz, emtricitabine and tenofovir reduces the risk of disease progression compared with multiple-pill formulations of the same regimen.
Introduction
In developed countries, many patients with HIV infection start antiretroviral therapy (ART) on a single-tablet once a day regimen. Such regimens are popular with patients because they are simple to take [1] , and this has encouraged the pharmaceutical industry to develop single-tablet regimens (STRs) using existing drugs. However, the existing drugs may become available in a cheaper generic form while the STR is still under patent. Public health systems could potentially use these generics to reduce drug costs and transfer savings to prevention and detection programmes, leading to better public health outcomes [2] .
Treatment guidelines recommend STRs [3] [4] [5] but, as yet, there is little evidence that these regimens are better than a multiple-pill formulation of the same regimen. In theory, STRs improve adherence to ART by reducing the pill burden of therapy, leading ultimately to a lower risk of disease progression. In practice, systematic reviews suggest that once-daily regimens lead to better adherence than twice-daily regimens but that this has little effect on virological suppression [1, 6, 7] . Some studies have compared single-tablet once-daily regimens to alternatives with different components and these studies suggest better adherence with the STR [8] . One study suggests that reducing the pill count in the same once-daily regimen from three to two may improve adherence [9] . There are no data with which to assess whether reducing the number of pills in a once-daily regimen lowers the risk of disease progression in HIV infection. As a consequence, economic evaluations of STRs have been based on projecting clinical outcomes from a mathematical simulation of HIV infection rather than on real-world data [10] .
In this study, we assessed whether the one-pill combination of efavirenz, emtricitabine and tenofovir reduces the risk of AIDS or death in treatment-na€ ıve HIV-infected patients starting ART compared with two-or three-pill formulations of the same regimen. We aimed to provide estimates from real-world data for future health economic modelling. Our analysis is based on data from the Antiretroviral Therapy Cohort Collaboration (ART-CC) of observational HIV-infected cohorts from Europe and Northern America.
Methods

Patient selection
The ART-CC was set up to study the prognosis of HIV-1-positive ART-na€ ıve adults [11] . The 2013 update of ART-CC includes data from 20 observational cohorts in Europe and North America but not all cohorts contributed data to this study. Cohort representatives were asked to confirm that, in their data, one-, two-and three-pill formulations of the same regimen could be identified. In cohorts where that was possible, we then selected all ART-na€ ıve patients starting one of the following efavirenz-based regimens: (1) the one-pill formulation of efavirenz, tenofovir and emtricitabine (Atripla â , Bristol-Myers Squibb, Princeton, New Jersey, USA and Gilead Sciences, Foster City, California, USA); (2) the two-pill formulation of efavirenz, tenofovir and emtricitabine (efavirenz plus Truvada â , Gilead Sciences, Foster City, California, USA); (3) the three-pill formulation of efavirenz, tenofovir and either lamivudine or emtricitabine, all as single tablets. In general, lamivudine or emtricitabine can be considered as interchangeable; however, there could be an increased risk of mutations following virological failure when patients receive lamivudine [12, 13] .
Statistical methods
Our primary outcome was the time from starting ART to a first new or recurrent AIDS event or death. Patients were included in our analyses from the time they started ART until this outcome, 6 months after a last visit (if lost to follow-up), the end of the study (administrative censoring), or any change in regimen components or formulation (artificial censoring) -whichever came first. We used Cox regression models to analyse these data. The exposure of interest in our models was the number of pills in the regimen. Models included covariates (specified in the analysis plan) to adjust for differences between the patients starting one-, two-or three-pill regimens. The covariates in our models were sex, injecting drug use as the mostly likely mode of HIV infection and -when starting ART -age, a previous AIDS event, calendar year, log 10 HIV RNA and CD4 cell count. We represented CD4 cell count in our models as a linear spline [14] with a knot at 200 cells/lL [15] . All models were stratified by cohort so that each cohort had its own baseline hazard function. Model parameters are reported as the estimated hazard ratio (HR) and its 95% confidence interval (CI). We expected that, if there was a difference in the risk of AIDS or death, this difference would be greater between two-and one-pill regimens than between threeand two-pill regimens. We followed a three-step modelling process.
First, we fitted two separate proportional hazards models, one for the choice between two-and one-pill regimens and a second for the choice between three-and two-pill regimens, with each model fitted to a subset of the data. With these separate models, we restricted data to those years in which clinicians were actually prescribing both regimens to their patients and we removed patients not followed for at least 1 month. We assumed that early events -in the first month on ART -would not be influenced by the number of pills in the regimen but would more likely reflect an unmasking of a unknown existing AIDS-defining infection or a clinical worsening and reoccurrence of a known infection [16] .
Secondly, we fitted a joint nonproportional hazards model to all data -including data from the first month -to make sure that a joint model could reproduce estimates seen in the two separate models. In the joint model, we estimated two hazard ratios -one for the first month on ART and one for follow-up after 1 month -for each of two indicators of exposure: two pills vs. one, and three pills vs. two.
Thirdly, we used parameters from the joint model to predict the probability of an AIDS event or death in a hypothetical future population where patients would be treated with either one pill or three pills. This hypothetical future population comprised all the patients in this study subject to a common baseline hazard across all cohorts, rather than a separate hazard for each cohort, because we can only predict probabilities at event times and some smaller cohorts had no events near the times of interest (1, 2 and 3 years on ART). We then calculated the number of patients who would need to be exposed to a one-pill regimen rather than a three-pill regimen over a given period to avoid one additional AIDS event or death by averaging risk differences across the patients in this hypothetical future population [17] .
All models were fitted in SAS 9.4 (SAS Institute, Cary, NC, USA); published SAS code was used to estimate AIDS event-free survival probabilities for models with timevarying hazards and to calculate the number of patients who would need to be exposed to avoid one additional event [17, 18] .
Sensitivity analyses
We carried out a range of sensitivity analyses. The methods used for these analyses and their results are described in full in the Supporting Information and are only briefly noted here.
First, our use of 1 month to separate early events from later events is somewhat arbitrary. While many immune reconstitution inflammatory syndrome (IRIS) events will be reported within weeks of starting ART [16] , such events can occur up to 3 months after starting ART or even later [19] . We therefore also estimated HRs for each exposure before and after either 3 or 6 months on ART (Appendix A, Supporting Information).
Secondly, we present results for a joint model with and without including calendar year as a covariate because of the correlation between calendar year and the number of pills in the regimen, our exposure of interest (Appendix B, Supporting Information).
Thirdly, in our main analysis, we did not categorize continuous confounders such as age, viral load, CD4 cell count or calendar year when starting ART. We provide sensitivity analyses to check that our use of continuous confounders has not misrepresented the evidence for an association between exposure and outcome (Appendix C, Supporting Information).
Fourthly, we also fitted a joint model using stabilized inverse probability of censoring weights [20] to allow for differences in patients remaining on each formulation over time. These weights allow for various scenarios where certain sorts of patients are more likely to switch to other regimens or to the same regimen with fewer pills (Appendix D, Supporting Information).
Finally, we also analysed a secondary outcome: time to virological failure, a first new or recurrent AIDS event or death. For this outcome, we fitted a Cox regression model appropriate for interval censored data [21] . Virological failure is interval censored because it is only known to have occurred at some point between one RNA measurement and the next (Appendix E, Supporting Information).
Results
Study population
Our main analysis was of 11 739 treatment-na€ ıve patients starting ART with efavirenz, tenofovir and either lamivudine or emtricitabine (Fig. 1) . Patients starting this regimen with one pill (rather than two or three pills) were less likely to be female, to have been infected with HIV through injecting drug use and to have had a previous AIDS event, and on average had a lower viral load and a higher CD4 cell count ( Table 1 ). The median time to the primary outcome or censoring was 11 months in these patients, with 386 AIDS events and 87 deaths, but follow-up often ended in artificial censoring because many patients on two-or three-pill regimens switched to the same regimen with fewer pills (Tables D1 to D5 in Appendix D, Supporting Information). Unadjusted rates of AIDS events or deaths were lower in patients on one pill than in those on two or three pills -with 20, 35 and 48 such events per 1000 years of treatment for patients on one, two and three pills, respectively. However, because of the high rate of events within the first month (Table F1 in Appendix F, Supporting Information), after 1 month there were only 12, 26 and 31 such events per 1000 years of treatment for patients on one, two and three pills, respectively.
Modelling
Clinicians were prescribing two-or one-pill regimens to their patients during the period 2006 to 2012 (Table B1 in Appendix B, Supporting Information). A model fitted to data for patients starting the regimen during this period -and including only patients followed for at least 1 month -suggests that two pills rather than one was associated with an increase in the risk of AIDS or death (HR 1.37; 95% CI 0.94 to 2.00; Table 2 ). During the period 2004 to 2008, clinicians were prescribing three-or two-pill regimens to their patients. A model fitted to these data suggests that three pills rather than two did not appreciably add to that increase in risk (HR 1.19; 95% CI 0.75 to 1.88).
A KaplanÀMeier plot for all our data shows how the association between the number of pills in the regimen and the risk of AIDS or death changed over time (Fig. 2) . In the log-minus-log plot of AIDS event-free survival against log survival time, the line for two pills crosses the line for one pill in the first few months of treatment. If a proportional hazards model were appropriate for these data, the two lines would not cross [22] . Therefore, when modelling all our data, we estimated different HRs before and after 1 month on ART. This joint model reproduced the point estimates seen in the two separate models for associations after 1 month on ART between the number of pills in the regimen and the risk of AIDS or death (Table 2) . However, because the joint model used all the data, its estimates were more precise.
This joint model also suggests that patients treated with a two-pill regimen had a lower risk of AIDS or death in the first month on ART (HR 0.65; 95% CI 0.44 to 0.95) than patients treated with a one-pill regimen. This was unexpected. Patients starting a one-pill regimen had early AIDS events at an appreciably lower CD4 cell count than those starting two-or three-pill regimens (Table F1 in Appendix F, Supporting Information). It is possible that this reflects changes over time in the monitoring of individuals at risk of HIV infection, in the treatment of opportunistic infections, or in the diagnosis of IRIS events (Appendix F, Supporting Information). We would not expect such changes in the past to apply to a future population where patients were treated with either the STR or three generic drugs. In both separate and joint models, there was a strong correlation between the parameter estimate for calendar year and parameter estimates for the number of pills in the regimen (Table B2 in Appendix B, Supporting Information). Estimates for the association between calendar year and the risk of AIDS or death were imprecise with wide confidence intervals ( Table 2) . Fitting a simple Cox model to the short period when all three formulations were being prescribed (2006 to 2008) does suggest that our models are overestimating the association between calendar year and the primary outcome (Appendix B, Supporting Information). Because of the strong correlation, if the association with calendar year is overestimated, the association with exposure will be underestimated. In economic modelling, it may be better to use estimates that overestimate rather than underestimate the benefits of current treatment guidelines recommending STRs, so that any decision to replace an STR with generic drugs is conservative. A joint model without calendar year as a covariate led to higher HRs for exposure parameters, as expected (Table 2) .
In sensitivity analyses, estimates of the association between the number of pills and the risk of AIDS or death varied predictably when using either 3 or 6 months rather than 1 month to separate early events from later events, consistent with a change in HRs within the first few months on ART (Appendix A, Supporting Information). In all models, later HRs implied that, after the change, two pills rather than one was associated with an increase in the risk of AIDS or death but three pills rather than two did not appreciably add to that increase. Estimates were not materially different when using categorical covariates rather than continuous covariates (Appendix C, Supporting Information), or when using inverse probability of censoring weights (Appendix D, Supporting Information). With our secondary outcome (time to virological failure, an AIDS event or death), we were not able to reproduce estimates seen with the primary outcome unless we used 3 months rather than 1 month to separate early events from later events and fitted a model without calendar year as a covariate (Appendix E, Supporting Information). Interval censoring makes it difficult to estimate early HRs in the joint model: interval censoring implies that we do not know exactly when virological failure occurred between two RNA measurements and, for most patients, the time between starting ART and the next RNA measurement was > 1 month.
Number needed to be exposed (NNE)
If we were to treat future patients with either the STR or three generic drugs, we would expect no difference in the risk of AIDS or death during their first month on ART.
We therefore set early HRs to 1 when predicting the probability of an AIDS event or death from our joint model. With this change made, 77 patients would need to be exposed to a one-pill regimen rather than a three-pill regimen for 1 year to avoid one additional AIDS event or death (Table 3) . If we kept early HRs as estimated, rather than setting them to 1, it made little difference (NNE = 72) because the two early HRs only affect the probability of events within the first month and were opposite in direction. For practical reasons, we assumed a common baseline hazard rate for all cohorts in our Fig. 2 The probability of event-free survival over time for antiretroviral-na€ ıve patients starting efavirenz (EFV), tenofovir (TDF) and either lamivudine (3TC) or emtricitabine (FTC) as either one, two or three pills. KaplanÀMeier plots show the probability of remaining alive and without an AIDS event over time for patients: starting two-or one-pill regimens over the period 2006 to 2012 (n = 8911); starting three-or two-pill regimens over the period 2004 to 2008 (n = 3914); and starting any of these three regimens at any time (n = 11 739). The final plot (bottom right) is a plot of log[Àlog(probability of event-free survival)] against log(time) for patients starting any of the three regimens at any time.
The line for a two-pill regimen crosses the line for a one-pill regimen during the first few months of exposure.
hypothetical population. We can only predict probabilities at event times, and some smaller cohorts had no events near the times of interest (1, 2 and 3 years on ART). We could instead use the baseline hazard rate seen in one of the larger cohorts for our hypothetical population. The baseline hazard rate from the AIDS Therapy Evaluation (ATHENA) cohort gave similar results to a common baseline hazard rate (NNE = 73). However, predicting from a model without calendar year as a covariate led to fewer patients needing exposure for 1 year with one pill rather than three to avoid one additional AIDS event or death (NNE = 61) because of this model's higher HRs for exposure parameters. Preliminary calculation of NNEs for the secondary outcome suggests that the potential cost savings from using three pills rather than one could be greater than first reported (Appendix E, Supporting Information).
Discussion
Economic modelling shows that replacing patented STRs with generic drugs could lead to substantial savings for health systems in the USA and UK [2, 10, 23] . The cost of antiretrovirals is more than half the total cost of HIV heath care [24] , and recent treatment initiatives -test and treat regardless of CD4 cell count and pre-exposure prophylaxis -are likely to increase both the absolute cost of antiretrovirals and their percentage of total costs. With either initiative, generics may be needed to contain costs [25, 26] . However, uncertainty about the comparative effectiveness of once a day regimens formulated as one, two or three pills has added to the uncertainty of economic modelling and health economists have asked for better data [10] . We show that a one-pill regimen has a lower relative risk of an AIDS event or death than a regimen with several pills for ART-na€ ıve patients remaining on a first regimen of efavirenz, tenofovir and either lamivudine or emtricitabine for more than 1 month. This decrease in risk is mostly associated with using a one-pill regimen instead of a two-pill regimen, rather than using a two-pill regimen instead of a three-pill regimen. Using these results, we predict that 77, 60 and 48 patients would need to be exposed to a one-pill regimen rather than a three-pill regimen for 1, 2 and 3 years, respectively, in order to avoid one additional AIDS event or death. The combination of efavirenz, tenofovir and emtricitabine is no longer a recommended first regimen in many developed countries [4, 5, 27] . However, it is widely used and those successfully treated with it are likely to remain on it. Indeed, those successfully treated with it are likely to be more open to switching to a multiple-pill generic formulation in order to reduce the cost of their treatment [28] . The combination is now considered an alternative regimen because of concern over the tolerability of efavirenz [4, 27] . So, our results represent an upper limit to the benefit one might logically expect from other once a day STRs over multiple-pill formulations of the same regimen. This is because the anchor drug in other STRs -dolutegravir, elvitegravir or rilpivirine -is likely to prove more tolerable than efavirenz [29] [30] [31] . Tolerability is a strong driver of adherence [32] [33] [34] and some of the improvement in adherence with an STR comes about because patients are not able to take just part of their regimen [33] [34] [35] . Our results could be used to evaluate any premium paid for other STRs over multiple-pill formulations of the same regimen by assuming that our results represent a best case scenario. Deliberate nonadherence (rather than accidental) could explain why most of the reduction in the risk of AIDS or death in this study came from using a one-pill regimen rather than a twopill regimen [36] . With a one-pill regimen, patients cannot take just part of their regimen; with two-or three-pill regimens, patients can avoid taking efavirenz while still taking the other drugs.
The combination of efavirenz, tenofovir and emtricitabine is the preferred first regimen in developing countries [37] . However, our results do not easily generalize to this setting. Adherence to a regimen may well be higher in this setting [38] and access to both care and treatment is probably a more important determinant of treatment success than adherence [39, 40] . STRs then offer additional advantages beyond improved adherence, with supply chain and stock management easier when only a single tablet is involved [41] .
The strengths of this study are data collected in routine clinical practice on a large number of patients so that we were able to assess the association between the number of pills in the regimen and disease progression in patients Table 3 The number of patients who would need to be exposed to a one-pill regimen rather than a three-pill regimen to avoid one additional AIDS event or death ATHENA, AIDS Therapy Evaluation; HR, hazard ratio.
taking the same once a day regimen. An observational study of this sort is probably the best way to evaluate the effect of STRs on disease progression. A pragmatic randomized controlled trial would be difficult: blinding is impossible so that differential dropout is likely [42] with a loss of randomization; adherence is likely to be greater and sustained for longer in a clinical trial setting [43] ; and large numbers of patients would need to be enrolled and followed for > 1 year in order to evaluate the effect on relatively rare events [44] . Well-designed observational studies do not necessarily overestimate the effects of interventions compared with randomized controlled trials [45] [46] [47] . As in any observational study, our adjustment for confounding variables may be incomplete. We had difficulty adjusting for some anticipated confounding effects because of a strong correlation between calendar time, a surrogate for these unmeasured confounding effects, and the number of pills in the regimen, our exposure of interest. In economic modelling, it may be better to use NNEs that overstate rather than understate the benefit of current treatment guidelines recommending one-pill once a day regimens, because medical decision makers are typically risk averse when faced with new uncertain treatment strategies [48, 49] . Using a model without calendar time as a covariate, we predict that 61, 48 and 38 patients would need to be exposed to one pill rather than three pills for 1, 2 and 3 years, respectively, in order to avoid one additional AIDS event or death. These NNEs are still high compared with those reported for other pharmaceutical interventions [50] . Note that further improvements in standard patient care would imply a lower incidence of AIDS or death in a future population than in these data and, as a consequence, higher NNEs when exposed to a one-pill regimen rather than a three-pill regimen than those predicted here. We did not have sufficient events to estimate an association between the number of pills in the regimen and mortality alone. Our results are based on treatment-na€ ıve patients and do not show what would happen if patients currently treated with one pill were then switched to three. We did not have data on adherence that could be used to assess whether the number of pills in the regimen was associated with clinical outcomes through adherence.
In general, results from meta analyses and individual studies show that STRs improve adherence to ART and are consistent with some slight reduction in the relative risk of virological failure [1, [6] [7] [8] 42] . Studies may find no significant difference in virological failure between STRs and multiple-pill regimens, but often there are few failures and estimates are in the direction of benefit [1, 42] .
And, as noted above, benefit is likely to be less apparent in the setting of a randomized controlled trial.
We show that the one-pill combination of efavirenz, emtricitabine and tenofovir was associated with a modest decrease in the risk of progression to AIDS or death compared with two-or three-pill formulations of the same regimen. This does not imply that an STR should be used rather than a multiple-pill formulation of the same regimen using generic drugs. Rather, we provide statistics that could be used to evaluate whether STRs are more cost-effective than other formulations. Our statistics could be used either as model inputs or to calibrate or validate models based on other data. If undiagnosed HIV infection is the limiting factor in the cascade of HIV care [2] , then saving money on drug costs could fund prevention and detection programmes leading to better public health outcomes.
